Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Novavax (NVAX) in Focus: Stock Moves 8.3% Higher

11h zacks
Novavax, Inc. (NVAX - Free Report) was a big mover last session, as the company saw its shares rise over 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $1.88 –$2.23 in the past one-month time frame, witnessed a sharp increase yesterday. (123-0)

Regeneron Annual Report, Earnings Forecast And Stock Valuation

2018-02-19 seekingalpha
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a fully integrated biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. It has six products in market: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST and ZALTRAP. The company has 15 product candidates in development based on its VelocImmune antibody development technology. (12-0)

REGN / Regeneron Pharmaceuticals, Inc. / Capital World Investors - SC 13G/A (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* Regeneron Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 75886F107 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of

REGN / Regeneron Pharmaceuticals, Inc. / Capital World Investors - SC 13G/A (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* Regeneron Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 75886F107 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of

Peanut Allergy Patch Gets FDA Review - Bloomberg

2018-02-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (17-2)

A Security Selection Method That Beats The Market - ValueWalk

2018-02-14 valuewalk
Since June 8th, I’ve been posting Portfolio Armor‘s top ten names each week. These names are ranked based on my site’s estimate of their potential returns over the next 6 months, net of hedging costs. As of Friday, we have actual 6-month returns for the first 10 weekly cohorts. 9 out of 10 of them beat the SPDR S&P 500 ETF (SPY), and the average 6-month performance of each weekly cohort was 21.13% versus 12. (166-1)

REGN / Regeneron Pharmaceuticals, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 10 REGENERON PHARMACEUTICALS INC COMMON STOCK Cusip #75886F107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #75886F107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 813,612 Item 6: 0 Item 7: 5,629,358 Item 8: 0 Item 9: 5,629,358 Item 11: 5.

REGN / Regeneron Pharmaceuticals, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 10 REGENERON PHARMACEUTICALS INC COMMON STOCK Cusip #75886F107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #75886F107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 813,612 Item 6: 0 Item 7: 5,629,358 Item 8: 0 Item 9: 5,629,358 Item 11: 5.

REGN / Regeneron Pharmaceuticals, Inc. EX-24

2018-02-12 sec.gov
Exhibit 24   POWER OF ATTORNEY   Know all by these presents that the undersigned hereby constitutes and appoints each of Leonard S. Schleifer, Robert E. Landry, Joseph J. LaRosa, Richard Gluckselig, and Beverly Dubs, signing singly, the undersigned’s true and lawful attorney-in-fact to:   (1)                                 execute for and on behalf of the undersigned, in the undersigned’s capacity as a director or officer of  Regeneron Pharmaceuticals, Inc.

REGN / Regeneron Pharmaceuticals, Inc. EX-24

2018-02-12 sec.gov
Exhibit 24   POWER OF ATTORNEY   Know all by these presents that the undersigned hereby constitutes and appoints each of Leonard S. Schleifer, Robert E. Landry, Joseph J. LaRosa, Richard Gluckselig, and Beverly Dubs, signing singly, the undersigned’s true and lawful attorney-in-fact to:   (1)                                 execute for and on behalf of the undersigned, in the undersigned’s capacity as a director or officer of  Regeneron Pharmaceuticals, Inc.

Regeneron - Levels To Regenerate?

2018-02-11 seekingalpha
This is comforting in combination with the strong growth of the products in collaboration with Sanofi. (135-0)

Updating The Bullish Case For Regeneron As The Stock Drops

2018-02-09 seekingalpha
REGN had a modest beat for revenues and EPS, but after trading up early in the day, sold off with the market and the biotech sector. (79-0)

REGN / Regeneron Pharmaceuticals, Inc. / VANGUARD GROUP INC - 3G (Passive Investment)

2018-02-09 sec.gov
regeneronpharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 0 )*       Name of issuer:  Regeneron Pharmaceuticals Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  75886F107     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedu

REGN / Regeneron Pharmaceuticals, Inc. / VANGUARD GROUP INC - 3G (Passive Investment)

2018-02-09 sec.gov
regeneronpharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 0 )*       Name of issuer:  Regeneron Pharmaceuticals Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  75886F107     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedu

It's Like 2008 Again - Cramer's Mad Money (2/8/18)

2018-02-09 seekingalpha
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, February 8. (342-2)


CUSIP: 75886F107